Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > July 17, 2025
Daily News
July 17, 2025
- Otsuka Taps Autoimmune Diseases as Strategic Pillar for Long-Term Growth
July 17, 2025
- Japan Approves Reimbursement for CureApp’s Alcohol Reduction Digital Therapeutic
July 17, 2025
- Japan Begins FY2026 CEA Reform Talks, Re-Designation after Market Expansion Up for Debate
July 17, 2025
- Nihon Medi-Physics to Deepen Theranostics Ties with Pharma under GE HealthCare
July 17, 2025
- Balversa Launched in Japan as 1st Genetically Targeted Drug for Bladder Cancer: J&J
July 17, 2025
- Towa Resumes Packaging Operations at Fire-Hit Yamagata Facility
July 17, 2025
- Astellas Employee Sentenced to 3.5 Years in China for Spying
July 17, 2025
- Nobelpharma’s Pediatric Sleep Aid Melatonin Wins Nod in China
July 17, 2025
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…